[1] BRUNETTI L, DESANTIS E R. Treatment of viral myocarditis caused by coxsackievirus B[J]. Am J Health Syst Pharm, 2008,65(2):132-137. [2] ELLIS C R, DI SALVO T. Myocarditis:basic and clinical aspects[J]. Cardiol Rev, 2007, 15(4):170-177. [3] SHANG Y, ZHANG W L. The clinical observation of astragalus injection combined with interferon-α of treatment on children with viral myocarditis[J]. Chin Mod Doct(中国现代医生), 2008,46(18):178. [4] DI W, FENG J, XU X Q, et al. The clinical observation of intravenous immune globulin combined with interferon-α-1b of treatment on children with viral myocarditis[J]. J Ningxia Med Coll(宁夏医学院学报), 2008,30(1):102-104. [5] DALIENO L, CALABRESE F, TONA F,et al. Sucessful treatment of enterovirus-induced myocarditis with interferon-α[J]. J Heart Lung Transplant,2003, 22(2):214-217. [6] KUHL U, PAUSCHINGER M, SCWIMMBECK P L, et al. Interferon-βtreatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction [J]. Circulation, 2003,107(22):2793-2798. [7] KUHL U, SCHULTHEISS H P. Viral myocarditis: diagnosis, aetiology and management[J]. Drugs, 2009, 69(10): 1287-1302. [8] NATHAN M, WALSH R, HARDIN J T, et al. Enteroviral sepsis and ischemic cardiomyopathy in a neonate:case report and review of literature[J]. Asaio J, 2008,54(5):554-555. [9] FREUND M W, KLEINVELD G, KREDIET T G, et al. Prognosis for neonates with enterrovirus myocarditis[J]. Arch Dis Child Fetal Neonatal ED, 2010,95(3):206-212. [10] KAO K L,YEH S L, CHEN C C. Myopericarditis associated with varicella zoster virus infection[J]. Pediatr Cardiol, 2010,31(5):703-706. [11] FERNADEZ-RUIZ M, MUNOZ-CODOCEO C, LOPEZ-MEDRANO F, et al. Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult:successful treatment with oral valacyclovir[J]. Intern Med, 2008,47(22):1963-1966. [12] HU Y F, QI F W. The advancement of immune pathogenesis and immune therapy on viral myocarditis[J].Foreigen Med Sci Pediatr(国外医学:儿科学分册), 2005,32(1):4-6. [13] KLUGMAN D, BERGER J T, SABLE C A, et al. Pediatric patients hospitalized with myocarditis:a multi-institutional analysis[J]. Pediatr Cardiol, 2010,31(2):222-228. [14] AMABILE N, FRAISSE A, BOUVENOT J, et al. Outcome of acute fulminant myocarditis in Children[J]. Heart, 2006, 92(9):1269-1273. [15] HAQUE A, BHATTI S, SIDDIQUI F J. Intravenous immune globulin for severe acute myocarditis in Children[J]. Indian Pediatr,2009,46(9):810-811. [16] ABE S, OKURA Y, HOYANO M, et al. Plasma contentrations of cytokines and neurohumoral factors in a case of fulminant myocarditis sucessfully treated with intravenous immunoglobulin and percutaneous cardiopulmonary support[J]. Circulation J, 2004,68(12):1223-1226. [17] CAMARGO P R, OKAY T S, YAMAMOTO L, et al. Myocarditis in children and detection of viruses in myocardial tissue:Implications for immunosuppresssive therapy[J]. Int J Cardiol,2011,148(2):204-208. [18] CHEN H, LIU L,YANG M. Corticosteroids for viral myocarditis[J]. Cochrane Database Syst Rev, 2006, 18(4):CD004471. [19] HIA C P,YIP W C L, TAI B C, et al. Immunosuppressive therapy in acute myocarditis: an 18 year systematic review[J]. Arch Dis Child, 2004, 89(6):580-584. [20] ZHANG Y, ZHU H, HUANG C, et al. Astragaloside Ⅳ exerts antiviral effects against coxsackie virus B3 by upregulating interferon-gamma[J]. J Cardiovasc Pharmacol,2006,47(2):190-195. [21] ZHANG Z C, LI S J, YANG Y Z, et al. Effect of astragaloside on cardiomyocyte apoptosis in murine coxsackievirus B3 myocarditis[J]. J Asian Nat Prod Res(亚洲天然产物研究), 2007,9(2):145-151. [22] WANG H, DING Y, ZHOU J, et al. The in vivo antiviral effects of salidroside from Rhodiola rosea L. against coxsackievirus B3[J]. Phytomedicine, 2009, 16(2-3):146-155. [23] SONG X, LIU Z, WANG H, et al. QiHong prevents death in coxsackievirus B3 induced murine myocarditis through inhibition of virus attachment and penetration[J]. Exp Biol Med(Maywood),2007 ,232(11):1441-1448. [24] ZHANG Y, ZHU H, YE G, et al. Antiviral effects of sophoridine against coxsackievirus B3 and its pharmacokinetics in rats[J]. Life Sci, 2006,78(17):1998-2005. [25] IMAZIO M, TRINCHERO R. Myopericarditis:Etiology, management, and prognosis [J]. Int J Cardiol, 2008, 127(1):17-26. [26] TOPKARA V K, DANG N C, BARILI F, et al. Ventricular assist device use for the treatment of acute viral myocarditis[J]. J Thorac Cardiovasc Surg,2006,31(5):1190-1191. [27] HETZER R, STILLER B. Technology insight: use of ventricular assist devices in children[J]. Nat Clin Pract Cardiovasc Med, 2006,3(7):377-386. [28] LI Y C, GE L S, YANG P L, et al. Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction[J]. Eur J Pharmacol, 2010,604(1-3):112-116. [29] YU F, CHEN R, TAKAHASHI T, et al. Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin[J]. Int J Cardiol, 2008, 129(3):414-421. [30] XIAO J, SHIMADA M, LIU W, et al. Anti-inflammatory effects of eplerenone on viral myocarditis[J]. Eur J Heart Fail, 2009,11(4):349-353.